An immune cell targeting T-cell lymphoma cells, its preparation method and application

By constructing chimeric antigen receptor T cells expressing anti-CD5 and anti-CD30 nanobodies, the problems of poor targeting and killing effects of CAR-T therapy in the treatment of T-cell lymphoma were solved, achieving effective killing of T-cell lymphoma cells and enhancing the therapeutic effect.

CN116655794BActive Publication Date: 2026-11-17SUN YAT SEN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310622964.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-29
Publication Date
2026-11-17
Estimated Expiration
2043-05-29

AI Technical Summary

Technical Problem

Current CAR-T therapies for T-cell lymphomas suffer from antigen escape and tumor-suppressive immune microenvironment, resulting in poor treatment efficacy and difficulty in effectively targeting T-cell lymphoma cells while preserving subsets of normal T cells and CAR-T cells.

Method used

Chimeric antigen receptors were constructed using genetic engineering techniques. Anti-CD5 and anti-CD30 nanobodies (NbCD5-1C and NbCD30-2B) were expressed in immune cells to form chimeric antigen receptor T cells (CAR-T cells). The cells were then transduced with recombinant lentiviruses to target and kill T-cell lymphoma cells.

Benefits of technology

It achieves specific targeted killing of T-cell lymphoma cells, improves the therapeutic effect of CAR-T therapy, and enhances the killing ability against CD5 and CD30 positive tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116655794B_ABST
    Figure CN116655794B_ABST
Patent Text Reader

Abstract

This invention discloses an immune cell targeting T-cell lymphoma cells, its preparation method, and its applications. The invention utilizes immunization of alpacas to obtain anti-CD5 and anti-CD30 nanobodies targeting antigenic proteins on the surface of T-cell lymphoma cells. Based on the obtained nanobodies, this invention further employs genetic engineering technology to express the nanobodies in immune cells, obtaining the corresponding immune cells. Verification has shown that the immune cells of this invention can target and effectively kill T-cell lymphoma cells, exhibiting anti-tumor capabilities. In addition to T-cell lymphoma cells, the immune cells of this invention can also target CD5 and CD30-positive tumor cells, for the treatment of CD5 and CD30-positive tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology. More specifically, it relates to an immune cell that targets T-cell lymphoma cells, its preparation method, and its application. Background Technology

[0002] T-cell lymphoma (TCL) is a highly heterogeneous group of malignant lymphocyte tumors originating from mature T cells, varying in tumor location, pathological features, and clinical manifestations. Although TCL has a low incidence, most TCL cases share the characteristics of aggressive disease progression and poor treatment response. Furthermore, most lymph node-type TCL cases respond poorly to conventional chemotherapy regimens, especially in patients whose disease progresses after treatment. In recent years, chimeric antigen receptor-T cells (CAR-T) have achieved great success in the treatment of hematological malignancies and are beginning to show promise in the treatment of T-cell lymphoma. However, during CAR-T therapy, the treatment effect of T-cell lymphoma is unsatisfactory due to antigen escape and the tumor-suppressive immune microenvironment. Therefore, new targeted therapies are still under active exploration, and there is a need to provide effective chimeric antigen receptor-T cells to optimize the therapeutic effect of CAR-T therapy for T-cell lymphoma.

[0003] Developing CAR-T therapy for T-cell malignancies requires targeting tumor T cells while preserving normal T cells and CAR-T cells, or at least some subsets of them. Most target antigens are shared between normal and tumor cells, making specific targeting of tumor cells challenging. Existing strategies for targeting tumor antigens while preserving CAR-T cells include: targeting pan-T antigens downregulated during CAR-T cell expansion, such as CD5, to prevent or reduce inter-CAR-T cell killing; or targeting antigens expressed only on a small subset of normal cells, such as CD4, CD30, or CCR4, to preserve most CAR-T cell subsets.

[0004] Nanobodies (Nb) are naturally occurring antibodies found in camel peripheral blood. Currently, most extracellular antigen-binding domains in CAR structures are designed based on single-chain antibody fragments (scFvs) of monoclonal antibodies, exhibiting high immunogenicity. Nb can reduce this immunogenicity. Simultaneously, Nb-based CAR-T therapy can fully leverage the advantages of T-cell immunotherapy, inducing the release of inflammatory cytokines and CD8+. +The cytotoxic effects of T cells. However, there are few existing nanobodies targeting CD5 and other targets. A strategy based on targeting tumor antigens while preserving CAR-T cells is needed to obtain suitable nanobodies, further leading to the development of immune cells with good killing effects against T-cell lymphoma cells, and ultimately, CAR-T therapy targeting T-cell malignancies. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to overcome the defects and deficiencies of the existing technologies and provide an immune cell that targets T-cell lymphoma cells, its preparation method and application.

[0006] The first objective of this invention is to provide a nanobody.

[0007] A second objective of this invention is to provide a chimeric antigen receptor.

[0008] A third objective of this invention is to provide a plasmid.

[0009] The fourth objective of this invention is to provide a recombinant lentivirus.

[0010] The fifth objective of this invention is to provide a chimeric antigen receptor immune cell.

[0011] The sixth object of the present invention is to provide a method for preparing the chimeric antigen receptor immune cells.

[0012] A seventh object of the present invention is to provide a pharmaceutical composition.

[0013] An eighth object of the present invention is to provide the use of the nanobody, the chimeric antigen receptor, the plasmid, the recombinant lentivirus, the chimeric antigen receptor immune cell, or the pharmaceutical composition in the preparation of a medicament for treating malignant tumors.

[0014] The above-mentioned objective of this invention is achieved through the following technical solution:

[0015] This invention provides a nanobody obtained by immunizing alpacas with recombinant CD5-His and CD30-His proteins. Specifically, the nanobody is an anti-CD5 or anti-CD30 nanobody. The anti-CD5 nanobody is named NbCD5-1C, and its CDR1, CDR2, and CDR3 amino acid sequences are shown in SEQ ID NO. 3, 5, and 7, respectively. The nucleotide sequences (genes) encoding CDR1, CDR2, and CDR3 are shown in SEQ ID NO. 4, 6, and 8, respectively. The amino acid sequence of the heavy chain variable region of NbCD5-1C is shown in SEQ ID NO. 1, and the nucleotide sequence encoding this heavy chain variable region is shown in SEQ ID NO. 2. The anti-CD30 nanobody is named NbCD30-2B. Its CDR1, CDR2, and CDR3 amino acid sequences are shown in SEQ ID NO. 11, 13, and 15, respectively, and the nucleotide sequences (genes) encoding CDR1, CDR2, and CDR3 are shown in SEQ ID NO. 12, 14, and 16, respectively. The amino acid sequence of the heavy chain variable region of NbCD30-2B is shown in SEQ ID NO. 9, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID NO. 10.

[0016] Based on the nanobody obtained in this invention, and using genetic engineering technology, this invention also constructs a chimeric antigen receptor and a chimeric antigen receptor immune cell with the nanobody as the antigen-binding domain. The immune cell can effectively kill CD5 and / or CD30-positive human T lymphoma cells. Therefore, this invention seeks protection for the chimeric antigen receptor, the chimeric antigen receptor immune cell, its preparation method, and its application.

[0017] The present invention provides a chimeric antigen receptor comprising a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling domain, and an intracellular signal transduction domain; wherein the antigen-binding domain is a nanobody against CD5 and / or CD30.

[0018] Specifically, the anti-CD5 nanobody is nanobody NbCD5-1C; the anti-CD30 nanobody is nanobody NbCD30-2B; the amino acid sequence of the nanobody and the nucleotide sequence of the encoding gene are as described above.

[0019] Optionally, the hinge region is a CD8 hinge region, the transmembrane domain is a CD8 transmembrane domain, the co-stimulatory signaling domain is a CD28, 4-1BB co-stimulatory signaling domain, and the intracellular signal transduction domain is a CD3ζ intracellular signal transduction domain.

[0020] As an optional implementation, the chimeric antigen receptor constructed using the nanobody NbCD5-1C is named SP-NbCD5-1C-CAR, and its complete amino acid sequence is shown in SEQ ID NO.17. The nucleotide sequence of the gene encoding this amino acid sequence is shown in SEQ ID NO.18.

[0021] As an optional implementation, the chimeric antigen receptor constructed using the nanobody NbCD30-2B is named SP-NbCD30-2B-CAR, and its complete amino acid sequence is shown in SEQ ID NO.19. The nucleotide sequence of the gene encoding this amino acid sequence is shown in SEQ ID NO.20.

[0022] As an optional implementation, the present invention utilizes nanobodies NbCD5-1C and NbCD30-2B to construct a bispecific chimeric antigen receptor, the complete amino acid sequence of which is shown in SEQ ID NO.21, and the nucleotide sequence of the gene encoding this amino acid sequence is shown in SEQ ID NO.22; the nanobodies NbCD5-1C and NbCD30-2B are tandemly linked by a (GGGGS)4 flexible peptide as a linker sequence.

[0023] The present invention also provides a plasmid containing the encoding gene of the nanobody described in the present invention, or the encoding gene of the chimeric antigen receptor described in the present invention.

[0024] Specifically, plasmids (vectors) include bacterial plasmids, expression vectors, lentiviral vectors, etc., which are well known in the field; in addition to containing the origin of replication, expression vectors may also contain marker genes and other translation control elements.

[0025] Optionally, the vector used in this invention for expressing nanobodies is pcDNA3.1-IRES-EGFP, which is constructed by inserting IRES and GFP into the vector pcDNA3.1.

[0026] Optionally, the vector used in this invention to construct a chimeric antigen receptor is a lentiviral vector pCppt; more specifically, it is pCppt-hCMV-IRES-GFP or pCppt-hCMV-IRES-RFP.

[0027] The present invention also provides a recombinant lentivirus, which is prepared from cells transfected with a plasmid containing the coding gene of the chimeric antigen receptor described in the present invention and a helper plasmid.

[0028] Specifically, there are two helper plasmids, psPAX2 and pMD2.G, and the cell is HEK 293T.

[0029] The present invention also provides a chimeric antigen receptor immune cell, wherein the cell expresses the chimeric antigen receptor described in the present invention; the immune cell is a T cell.

[0030] The present invention also provides a method for preparing the chimeric antigen receptor immune cells, wherein the method comprises transducing the encoding gene of any chimeric antigen receptor of the present invention into cells via lentivirus or retrovirus.

[0031] Optionally, in this invention, a recombinant lentiviral vector expressing the chimeric antigen receptor is constructed, and then transduced into cells via lentiviral packaging.

[0032] The present invention also provides a pharmaceutical composition comprising the chimeric antigen receptor immune cells described herein; the pharmaceutical composition further comprising any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient, or diluent.

[0033] The present invention also claims protection for the use of the nanobody, the chimeric antigen receptor, the plasmid, the recombinant lentivirus, the chimeric antigen receptor immune cell, or the pharmaceutical composition in the preparation of a drug for treating malignant tumors.

[0034] Specifically, the malignant tumor is a CD5 and / or CD30 positive tumor.

[0035] Optionally, the malignant tumor is a T-cell lymphoma.

[0036] Specifically, the T-cell lymphoma is CD5 and / or CD30 positive.

[0037] The present invention has the following beneficial effects:

[0038] This invention targets antigenic proteins on the surface of T-cell lymphoma cells and obtains anti-CD5 and anti-CD30 nanobodies by immunizing alpacas. Based on the obtained nanobodies, this invention further utilizes genetic engineering technology to express the nanobodies in immune cells, obtaining corresponding immune cells. Verification has shown that the immune cells of this invention can target and effectively kill T-cell lymphoma cells, exhibiting anti-tumor capabilities. In addition to T-cell lymphoma cells, the immune cells of this invention can also target CD5 and CD30-positive tumor cells, for the treatment of CD5 and CD30-positive tumors. Attached Figure Description

[0039] Figure 1 The results of the third round of ELISA for positive monoclonal anti-CD5 nanobodies.

[0040] Figure 2The results of the third round of ELISA for positive monoclonal nanobodies against CD30.

[0041] Figure 3 The results of flow cytometry identification of positive monoclonal anti-CD5 nanobodies are shown.

[0042] Figure 4 The results of flow cytometry identification of positive monoclonal anti-CD30 nanobodies are shown.

[0043] Figure 5 The results show the affinity of the nanobody NbCD5-1C as detected by ELISA; ***p<0.001, ****p<0.0001.

[0044] Figure 6 The results show the affinity of the nanobody NbCD5-1C as determined by the SPR method.

[0045] Figure 7 The affinity results for the nanobody NbCD30-2B, as detected by ELISA, are shown; p < 0.0001.

[0046] Figure 8 The results show the affinity of the nanobody NbCD30-2B as determined by the SPR method.

[0047] Figure 9 A schematic diagram of the structure of a recombinant lentiviral vector expressing Nb-CAR.

[0048] Figure 10 Results of in vitro functional validation of NbCD5-1C-CAR-T cells; **p<0.01, ****p<0.0001.

[0049] Figure 11 Results of in vitro functional validation of NbCD30-2B-CAR-T cells; ***p<0.001, ****p<0.0001.

[0050] Figure 12 The in vitro functional validation results of NbCD5-CAR-T, NbCD30-CAR-T, and bispecific NbCD5-CD30-CAR-T cells are shown. The top two figures represent the killing effect of NbCD5-CAR-T, NbCD30-CAR-T, and bispecific NbCD30-CD5-CAR-T cells against Karpas-299 cells that highly express CD30 and CD5 at different effector-to-target ratios. The bottom two figures represent the killing effect of NbCD5-CAR-T, NbCD30-CAR-T, and bispecific NbCD30-CD5-CAR-T cells against cells that express only CD30 and very little CD5 target antigen (CD30). + CD5- SupT1) Kill results at different effective-to-target ratios; **p<0.01, ***p<0.001, ****p<0.0001.

[0051] Figure 13 The effects of NbCD5-CAR-T, NbCD30-CAR-T, and bispecific NbCD30-CD5-CAR-T cells on tumors in a mouse tumor-bearing model were evaluated; *p<0.05, ***p<0.001, ****p<0.0001, and no significant difference was observed in ns. Detailed Implementation

[0052] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.

[0053] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0054] In this invention, the terms "nanobody," "VHH," and "VHH antibody fragment" are used interchangeably and refer to the variable domain of a single heavy chain of an antibody found in camels. In the absence of a light chain, a nanobody has three CDRs, namely CDR1, CDR2, and CDR3, and is the smallest antigen-binding fragment with full function. Typically, a naturally occurring antibody lacking both the light chain and the heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a nanobody (Nb) consisting of only a single heavy chain variable region, also known as a VHH. Nanobodies / single-domain antibodies, as a novel type of small molecule antibody fragment, are obtained by cloning the heavy chain variable region (VHH) of a naturally occurring camel heavy chain antibody.

[0055] Example 1: Obtaining anti-CD5 and anti-CD30 nanobodies

[0056] 1. Preparation of CD5 antigen protein

[0057] RNA was extracted from human Karpas-299 cells using an RNA extraction kit, following the instructions from Vazyme. The instructions for the III RT SuperMix for qPCR (+gDNA wiper) reverse transcription kit are as follows: Extracted RNA is reverse transcribed into cDNA. Using the cDNA as a template, the extracellular region gene sequence of the CD5 antigen protein is obtained by PCR. The primers used for PCR were designed based on the sequence with the reference gene accession number NM_014207.4, and the primer sequences are shown below:

[0058] CD5 primer F: CGGCTCAGCTGGTATGACCC;

[0059] CD5 primer R: GGGGTTTGGATCCTGGCATG;

[0060] The extracellular region gene sequence of CD5 obtained by PCR amplification was ligated into the protein expression vector in 3.1 for recombinant expression, and purified by Ni column to obtain purified CD5-His protein.

[0061] 2. Preparation of CD30 antigen protein

[0062] The preparation of CD30 antigen is the same as that of CD5, the difference being the primers used for PCR. The primers used for CD30 PCR were designed based on the sequence referenced in the gene accession number NM_001243.5, and the primer sequences are shown below:

[0063] CD30 primer F: TTCCCACAGGATCGACCCTT;

[0064] CD30 primer R: CCCTGCATCCAGAACGGGCT;

[0065] The extracellular region gene sequence of CD30 obtained by PCR amplification was ligated into the protein expression vector in 3.1 for recombinant expression, and purified by Ni column to obtain purified CD30-His protein.

[0066] 3. Construction of nanobody libraries

[0067] Purified CD5-His and CD30-His proteins were used as antigens to immunize alpacas four times, once every two weeks. Each immunization administered 1 mg of antigen protein. Blood was drawn from the alpacas at each immunization for subsequent verification of the titer after the four immunizations. Six days after the final immunization, 50 mL of peripheral blood was drawn from the alpacas. Specifically, the volume of antigen used during immunization was less than 2 mL. The antigen protein and adjuvant were emulsified at a 1:1 volume ratio to form a homogeneous mixture, which was stored at 4°C. Each injection was administered near the lymph nodes in the alpaca's neck, on both sides, with two injection points on each side, and 0.4 mL of the mixed antigen injected at each point. The alpacas were observed for half an hour after immunization to confirm they were in good condition and showed no signs of discomfort. Peripheral blood mononuclear cells were isolated using density gradient centrifugation, and total RNA was extracted using Trizol. The RNA was then reverse transcribed into cDNA using a reverse transcription kit. Using the obtained cDNA as a template, antibody fragments were amplified by PCR in two rounds. The first round of PCR yielded the variable and constant regions VHH-CH2 of the nanobody, and the second round yielded the variable region VHH. After digestion with sfi I restriction enzyme, the fragments were ligated into the phage plasmid pComb3XSS vector. The ligation product of the constructed phage recombinant plasmid was electroporated into the phage host bacterium SS320 for amplification and purification of the phage library, resulting in an alpaca-immune nanobody phage library. To verify the VHH gene insertion rate, single colonies were randomly selected from the library construction plate. Colony PCR and Sanger sequencing of positive colonies were performed to calculate the correct insertion rate of the VHH gene and to detect sequence diversity.

[0068] The construction results of the nanobody library show that the present invention successfully constructed a library with a capacity of 4.32 × 10⁻⁶. 8 The nanobody library met the library construction requirements, indicating that the library has the potential to yield Nbs with high specificity and sequence diversity, which can be used for subsequent screening. Furthermore, the positive clone rate reached 100%, and sequencing results showed that all sequences were independent and non-repetitive, with good sequence diversity. Phylogenetic analysis of the sequences showed good sequence independence.

[0069] 4. Amplification and enrichment screening of nanobody phage libraries

[0070] The constructed nanobody SS320 E. coli library was transferred to 2-YT liquid medium containing tetracycline and cultured at 37°C and 200 rpm until the OD value reached 0.5. Helper phage M13K07 was then added for infection. After gentle mixing, the culture was incubated at 37°C for 30 min. Ampicillin was added to the 2-YT medium, and the culture was incubated overnight at 37°C and 200 rpm to amplify the phage displaying the nanobody. The overnight culture was transferred to a 50 mL centrifuge tube, centrifuged, and the supernatant was collected. 20% (wt / vol) PEG6000 / 2.5M NaCl solution was added to purify the phage. The supernatant was discarded after centrifugation, and the precipitate was resuspended in PBS and centrifuged again. The supernatant was transferred to a new centrifuge tube, and 20% (wt / vol) PEG6000 / 2.5M NaCl solution was added to reprecipitate the phage. The supernatant was discarded after centrifugation, and the precipitate was resuspended in 1 mL of PBS. In PBS; after centrifugation, the supernatant was transferred to a new centrifuge tube, glycerol was added to a final concentration of 20%, and the tube was stored at -80°C for phage screening.

[0071] Phage screening: Immunotubes were coated with CD5 and CD30 antigen proteins, blocked, and then incubated with purified and concentrated phage libraries. Unbound phages were washed away, and the protein-bound phages were eluted for amplification and purification. Simultaneously, host bacterial dilutions were performed for plate testing to determine the phage titer (nanobody phage titer determination: phages were diluted 10-fold, and different dilutions were used to infect SS320 bacteria in logarithmic growth phase. The bacteria were incubated overnight at 37°C, and the titer was obtained by counting the colonies on the second day). This constituted the first round of screening. After three rounds of screening, the final single clones plated were selected for phage amplification and purification. The binding ability of the screened antibodies to the antigen proteins was verified using a phage single-clone ELISA assay.

[0072] 5. Screening and identification of positive monoclonal antibodies

[0073] Single clones were selected from the SS320 E. coli library obtained after three rounds of screening and cultured. Single-clonal phages were prepared by infection with helper phage M13K07. The single-clonal phages were added to culture plates coated with CD5-His or CD30-His proteins and incubated at room temperature for 1 hour. After washing the plates with 200 μL PBST, anti-M13K07-HRP antibody was added and incubated at room temperature for 1 hour. After washing the plates with 200 μL PBST, 100 μL of TMB single-component chromogenic solution was added and incubated at room temperature for 30 minutes, followed by the addition of 100 μL of stop solution. The absorbance at 450 nm was measured using a microplate reader (positive clones were determined by an OD450 reading ratio of the experimental wells to the control group (BSA) greater than or equal to 2).

[0074] After diluting and plating the final selected phages onto plates, two rounds of monoclonal phage ELISA were performed. In the first round of ELISA, five 96-well plates were selected for monoclonal assays. Based on the results of the first round, 96 monoclonal clones with the highest OD450 values ​​were selected for the second round of ELISA. The top 24 positive clones were then selected for the third round of ELISA. The results of the third round of ELISA for the anti-CD5 nanobody positive monoclonal clones are shown below. Figure 1 As shown, by Figure 1 Twenty-one positive monoclonal antibodies were obtained against the CD5 antigen. These positive monoclonal antibodies were subjected to Sanger sequencing and sequence alignment using DNAMAN software. Repeated sequences were removed, resulting in six distinct CD5-ELISA positive monoclonal antibodies. Flow cytometry was then used to identify the selected positive clones, and the antibodies were further purified for antigen-antibody ELISA binding assays to determine sequence specificity.

[0075] The results of the third round of ELISA for anti-CD30 nanobody positive monoclonal antibodies are as follows: Figure 2 As shown, by Figure 2 Sixteen positive monoclonal antibodies were obtained against the CD30 antigen. These positive monoclonal antibodies were subjected to Sanger sequencing and sequence alignment using DNAMAN software. Repeated sequences were removed, resulting in 10 distinct CD30-ELISA positive monoclonal antibodies. Flow cytometry was then used to identify the selected positive clones, and the antibodies were further purified for antigen-antibody ELISA binding assays to determine sequence specificity.

[0076] Nanobodies that can bind to CD5 or CD30 antigen proteins have already been screened. However, given the potential steric hindrance between cell surface antigens and purified antigens, the screened nanobodies need to be validated through target cell screening. Therefore, flow cytometry was used to screen for nanobodies that can effectively bind to cells, and to further screen and remove false-positive clones. Purified monoclonal phages were co-incubated with cells for 1 hour, and unbound monoclonal phages were washed off the cells with PBS. Since the constructed phage vector carries a His tag sequence, anti-His-PE flow cytometry fluorescent antibodies were used to label Karpas-299 target cells that had bound His-tagged monoclonal phages, followed by identification using flow cytometry.

[0077] Flow cytometry identification results of anti-CD5 nanobody positive monoclonal antibodies are as follows: Figure 3 As shown, by Figure 3The results show that this invention identified a monoclonal antibody with a high flow cytometry positivity rate and obtained one anti-CD5 nanobody, which was named nanobody NbCD5-1C. The amino acid sequence of the heavy chain variable region of nanobody NbCD5-1C is shown in SEQ ID NO.1, and the nucleotide sequence encoding this heavy chain variable region is shown in SEQ ID NO.2. Specifically, the amino acid sequences of CDR1, CDR2, and CDR3 of nanobody NbCD5-1C are shown in SEQ ID NO.3, 5, and 7, respectively; and the nucleotide sequences encoding CDR1, CDR2, and CDR3 of nanobody NbCD5-1C are shown in SEQ ID NO.4, 6, and 8, respectively.

[0078] Flow cytometry identification results of anti-CD30 nanobody positive monoclonal antibodies are as follows: Figure 4 As shown, by Figure 4 The results show that this invention identified a monoclonal antibody with a high flow cytometry positivity rate and obtained one anti-CD30 nanobody, which was named nanobody NbCD30-2B. The amino acid sequence of the heavy chain variable region of nanobody NbCD30-2B is shown in SEQ ID NO. 9, and the nucleotide sequence encoding this heavy chain variable region is shown in SEQ ID NO. 10. Specifically, the amino acid sequences of CDR1, CDR2, and CDR3 of nanobody NbCD30-2B are shown in SEQ ID NO. 11, 13, and 15, respectively; and the nucleotide sequences encoding CDR1, CDR2, and CDR3 of nanobody NbCD30-2B are shown in SEQ ID NO. 12, 14, and 16, respectively.

[0079] Example 2: Recombinant Expression and Affinity Determination of Nanobodies

[0080] 1. Recombinant expression of nanobodies

[0081] This invention involves linking the screened nanobody NbCD5-1C (shown in SEQ ID NO.2) to a human IgG-FC fragment using a flexible polypeptide linker ((GGGGS)4). (The FC fragment is linked to increase antibody expression yield and stability; it also acts as a tag protein to bind to Protein A for antibody purification.) Simultaneously, a signal peptide (MYRMQLLSCIALSLAL VTNS) is added to the N-terminus of the nanobody sequence. The SP-NbCD5-1C-Linker-FC fragment is inserted between the Nhe I and Not I restriction sites of the pcDNA3.1-IRES-EGFP plasmid to obtain the recombinant expression plasmid pcDNA3.1-SP-NbCD5-1C-Linker-Fc-IRES-EGFP. The correctly sequenced recombinant plasmid is extracted and transfected into HEK 293T cells for protein expression. After expression, the cell supernatant is collected, filtered, and centrifuged. The nanobody NbCD5-1C is purified by Protein A affinity chromatography to obtain high-purity NbCD5-1C.

[0082] The sequence of the IgG-FC fragment is shown below:

[0083] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0084] Using the same method, the recombinant expression plasmid pcDNA3.1-SP-NbCD30-2B-Linker-Fc-IRES-EGFP was constructed from the screened nanobody NbCD30-2B (SEQ ID NO.10). The correctly sequenced recombinant plasmid was extracted and transfected into HEK 293T cells for protein expression. After expression, the cell supernatant was collected, filtered, and centrifuged. The nanobody NbCD30-2B was purified by Protein A affinity chromatography to obtain high-purity NbCD30-2B.

[0085] 2. Affinity test

[0086] (1) ELISA detection of antibody affinity

[0087] The ability of the screened nanobodies to bind to antigen proteins was verified using an ELISA assay. The prepared CD5 or CD30 antigen proteins were coated overnight onto ELISA blank plates. Antibodies of different dilutions after expression and purification were used as analytes (primary antibodies to bind to the antigen proteins). Antibodies targeting the FC fragment were used as secondary antibodies to detect the binding of the nanobodies to the antigen proteins. To verify the stability of the antibody binding ability, a serial dilution ELISA assay was used to detect the affinity between the antibodies at different dilutions and the antigen proteins. BSA protein was used as a control.

[0088] (2) SPR method for detecting antibody affinity

[0089] The affinity of the antibodies was further detected using SPR (surface plasmon resonance) experiments and a Biacore T100 analysis system (the smaller the KD value, the greater the affinity of the antibody for its target). First, CD5-His or CD30-His proteins were covalently coupled to a CM5 sensor chip. Then, affinity was detected using nanobodies of different concentrations. Finally, software was used to determine the association and dissociation rate constants, and the affinity of NbCD5-1C for CD5 protein and NbCD30-2B for CD30 protein were measured.

[0090] The affinity results of the nanobody NbCD5-1C detected by ELISA method are as follows: Figure 5 As shown, by Figure 5 It can be seen that the NbCD5-1C antibody exhibits a good dose-response relationship after dilution; the binding ability decreases slowly after antibody dilution, and the dose-response curve is significantly different from that of the control group. The affinity results of the NbCD5-1C nanobody detected by the SPR method are as follows: Figure 6 As shown, by Figure 6 It can be seen that NbCD5-1C has a very high affinity for CD5 protein, with an affinity constant (KD) of 6.30 × 10⁻⁶. -11 The results show that the anti-CD5 nanobody (NbCD5-1C) obtained through screening and identification has a high affinity for human CD5 protein.

[0091] The affinity results of the nanobody NbCD30-2B as detected by ELISA method are as follows: Figure 7 As shown, by Figure 7 It can be seen that the NbCD30-2B antibody exhibits a good dose-response relationship after dilution; the binding ability decreases slowly after antibody dilution, and the dose-response curve is significantly different from that of the control group. The affinity results of the NbCD30-2B nanobody detected by the SPR method are as follows: Figure 8 As shown, by Figure 8It can be seen that NbCD30-2B has a very high affinity for CD30 protein, with an affinity constant (KD) of 4.17 × 10⁻⁶. -11 The results show that the anti-CD30 nanobody (NbCD30-2B) obtained through screening and identification has a high affinity for human CD30 protein.

[0092] Furthermore, by changing the target antigens, the specificity of the nanobodies NbCD5-1C and NbCD30-2B was tested. The results showed that NbCD5-1C did not bind when coated with CD30 antigen protein, and NbCD30-2B did not bind when coated with CD5 antigen protein. However, the monoclonal antibody scFv-CD30 targeting CD30 did have a certain binding ability with CD5 antigen protein. This indicates that the nanobodies NbCD5-1C and NbCD30-2B obtained by this invention have very low off-target properties and strong antigen specificity.

[0093] Example 3: Preparation and In Vitro Functional Verification of Nb-CAR-T Cells

[0094] 1. Construction of lentiviral vectors expressing Nb-CAR (Nb chimeric antigen receptor) structure

[0095] Before constructing the recombinant lentiviral vector, this invention constructed corresponding Nb-CAR structures using NbCD5-1C and NbCD30-2B, namely SP-NbCD5-1C-CAR and SP-NbCD30-2B-CAR.

[0096] The complete amino acid sequence of the SP-NbCD5-1C-CAR is shown in SEQ ID NO.17, and the nucleotide sequence encoding this amino acid sequence is shown in SEQ ID NO.18. The complete amino acid sequence of the SP-NbCD30-2B-CAR is shown in SEQ ID NO.19, and the nucleotide sequence encoding this amino acid sequence is shown in SEQ ID NO.20.

[0097] A recombinant lentiviral vector expressing the Nb-CAR was obtained by linking the Nb-CAR structure to the vector pCppt (pCppt-hCMV-IRES-GFP). Specifically, the recombinant lentiviral vector expressing SP-NbCD5-1C-CAR was named pCppt-hCMV-SP-NbCD5-1C-CAR-IRES-GFP, and the recombinant lentiviral vector expressing SP-NbCD30-2B-CAR was named pCppt-hCMV-SP-NbCD30-2B-CAR-IRES-RFP. A schematic diagram of the recombinant lentiviral vector expressing the Nb-CAR is shown below. Figure 9 As shown, by Figure 9 It can be seen that the entire Nb-CAR structure is located after the CMV promoter. The SP part refers to the signal peptide, the NbCD5-1C part is an anti-CD5 nanobody, the NbCD30-2B part is an anti-CD30 nanobody, and the CAR includes the CD8 hinge region, the CD8 transmembrane domain, the CD28, 4-1BB co-stimulatory signaling domain, and the CD3ζ intracellular signal transduction domain. The CAR is followed by an IRES sequence and linked to a GFP or RFP fluorescent protein.

[0098] 2. Lentiviral packaging

[0099] Lentiviral packaging is performed before CAR-T cell preparation.

[0100] Pretreatment of culture dishes with poly-L-lysine and HEK HEK293T cells were seeded into plates. The following day, after the cell density reached 80%, liposome reagent PEI-plasmid mixture was prepared in Opti-MEM medium (1 mL per 10 cm culture dish). The mixture contained 10 μg of the target vector pCppt-hCMV-SP-NbCD5-1C-CAR-IRES-GFP or pCppt-hCMV-SP-NbCD30-2B-CAR-IRES-RFP, 10 μg of the helper plasmid psPAX2, and 4 μg of pMD-2G. HEK293T cells were co-transfected with this mixture. 8–12 hours later, transfection was observed under a fluorescence microscope, and 10 mL of fresh medium was added. Lentiviral virus was recovered 48 hours after packaging. The virus solution was centrifuged at 500g to remove cell debris and filtered through a 0.45 μm filter. 10 mL of the virus solution was added to a 50 mL centrifuge tube, followed by the addition of virus concentrating reagent (3 mL of 50% PEG). Mix 6000 mL of 4 mol / L NaCl with 1.28 mL of PBS and place in a 4°C refrigerator overnight. The next day, centrifuge at 4°C, 4000 rpm for 40 min. A white precipitate will be visible at the bottom of the tube. Discard the supernatant, add an appropriate volume of KBM 581 medium to resuspend the lentivirus particles, and immediately infect T cells or aliquot and store at -80°C for later use.

[0101] 3. CAR-T cell preparation

[0102] After the lentivirus is packaged, CAR-T cells are prepared.

[0103] First, peripheral blood mononuclear cells (PBMCs) from healthy donors were collected and isolated: 10 mL of normal human peripheral blood was added to 40 mL of PBS solution and mixed well. Then, two 50 mL sterile centrifuge tubes were taken, and 25 mL of human lymphocyte separation medium was added to the tubes. 25 mL of the mixed peripheral blood was slowly added to the tubes to avoid disrupting the liquid layer. The tubes were centrifuged at 500 g for 40 minutes at room temperature with an acceleration of 5 and a deceleration of 0. After centrifugation, the middle milky white layer (PBMCs) was carefully aspirated into a new 50 mL centrifuge tube and diluted with 3 to 5 times the volume of PBS. The tubes were centrifuged at 350 g for 15 minutes at room temperature with an acceleration of 5 and a deceleration of 5. The supernatant was discarded, the cells were resuspended in PBS, and the tubes were centrifuged at 300 g for 5 minutes at room temperature. The supernatant was discarded.

[0104] CD8 cell sorting using CD8 magnetic beads: Cells were resuspended in PBS at 10 × 10⁻⁶ m² / g saturated. 6 cells / mL, at a rate of 1×10 6 Add 60 μL of the Cocktail from the Human CD8 Magnetic Bead Cell Negative Selection Kit (Guangzhou Peipu Biotechnology) to each cell, mix well, and incubate at room temperature for 15 minutes; add 10 volumes of PBS, centrifuge at 300g for 7 minutes at room temperature, and discard the supernatant; each 1×10 6 Add 60 μL of Streptavidin Particles from the Human CD8 Magnetic Bead Cell Negative Selection Kit to each cell, vortex to mix, and incubate at room temperature for 20 minutes; then resuspend the cells in PBS to a pH of 20–80 × 10⁶. 6 At a concentration of 100 cells / mL, with a volume of 9 mL, the cell suspension was transferred using a 5 mL Pasteur tube into three 12×75 mm flow cytometry tubes, 3 mL per tube. The tubes were then incubated in a BD IMagnet for 6–8 minutes. The supernatant was carefully aspirated into a centrifuge tube. Three more 12×75 mm flow cytometry tubes were prepared, and the process of incubating with the BD IMagnet was repeated twice. The cell suspension was then transferred to sterile 15 mL centrifuge tubes and centrifuged at 350 g for 5 minutes at room temperature. The supernatant was discarded. The initial CD8 cells were then separated. + T lymphocytes at a rate of 1×10 6 Cells were suspended at a concentration of 10 cells / mL in serum-free lymphocyte culture medium KBM581 (1% penicillin-dextrose antibody), and activated with anti-CD3, anti-CD28 and human IL-2 cytokines. The final concentrations of anti-CD3 and anti-CD28 were 25 μL / mL, and the final concentration of human IL-2 was 10 μg / mL. The cells were added to 6-well culture plates or T25 culture flasks and incubated in an incubator (37°C, 5% CO2).

[0105] Lentiviral infection: After 2 days of culture, use an automated cell counter to count the number of cells during culture, and aspirate a sufficient amount of cells (1–3 × 10⁻⁶). 6Add 1 mL of concentrated virus resuspension (10 mL of virus stock solution was concentrated into 1 mL of concentrated virus resuspension) to the concentrated virus resuspension, mix well, and then add at 5 × 10⁻⁶. 5 Cells were added at a density of 500 μL / 500 μL to 48-well cell culture dishes, 500 μL per well. The dishes were centrifuged at 37°C, 800 g for 90 minutes, and then placed in an incubator (37°C, 5% CO2). After 8–12 hours, the medium was replaced with fresh serum-free lymphocyte medium KBM581, and the dishes were placed in an incubator (37°C, 5% CO2) supplemented with human cytokines. The medium was changed and IL-2 cytokines were supplemented every 2–3 days. The culture was expanded to 7–14 days to obtain CD5-targeting Nb-CAR-T cells, named NbCD5-1C-CAR-T. Nb-CAR-T cells targeting CD30 were obtained using the same method and named NbCD30-2B-CAR-T.

[0106] 4. In vitro functional verification of CAR-T cells

[0107] To verify the in vitro biological activity of the prepared CAR-T cells, an in vitro killing experiment was conducted during the culture process by measuring the release of LDH using the Promega CytoTox 96 non-radioactive cytotoxicity assay kit.

[0108] CD8 cells infected with NbCD5-1C-CAR virus + T lymphocytes (NbCD5-1C-CAR-T) were used to kill Karpas-299 cells that highly expressed CD5 at different ratios. The experiment first involved digesting cultured positive target cells, Karpas-299 (CD5+) cells. + Human T-lymphoma cells), and control negative target cells Raji (CD5) - Human lymphoma cells), centrifuged at 500g for 5 min, resuspended and counted; experimental target cells were prepared according to a cell quantity of 10-1. 4 / Hole added to V-bottom 96-hole plate, CD8 + T lymphocytes were added to the target cell group at ratios of 10:1, 5:1, 2.5:1, 1.25:1, 0.625:1, and 0.3125:1, after being thoroughly mixed. The total volume was 150 μL. The background control group received an equal volume of serum-free KBM581 medium. The volume correction control group received an equal volume of serum-free KBM581 medium and 10 μL of 10× cell lysis buffer. The effector cell self-release group received only an equal volume of CD8+ T lymphocytes. The target cell self-release group received 10× CD8+ T lymphocytes. 4 10 target cells, with a maximum release group of 10 target cells. 4Each target cell was fully lysed in 16.7 μL of 10× cell lysis buffer (lysed before sample collection). For the spontaneous release group in KBM581 medium, 150 μL of KBM581 medium was added, and for the maximum release group in KBM581 medium, 150 μL of KBM581 medium was added, followed by 16.7 μL of 10× cell lysis buffer (lysed before sample collection). Each group had 3 subwells. After adding the samples, the cells were centrifuged at 500 g for 3 minutes at room temperature and incubated at 37°C for 24 hours.

[0109] Before sample collection, 16.7 μL of 10× cell lysis buffer was added to the maximum release group of target cells, and 16.7 μL of 10× cell lysis buffer was added to the maximum release group of KBM581 cells. The cells were incubated at 37°C for 1–2 h, and the culture plates were centrifuged at 500 g for 5 minutes at room temperature. Subsequently, 30 μL of supernatant was transferred from each well to a new flat-bottomed 96-well plate, and 30 μL of LDH reaction substrate was added. After reacting at room temperature in the dark for 30 minutes, 30 μL of stop solution was added, and the absorbance at 490 nm was measured. The cell killing ratio was calculated using the following formula:

[0110] Kill rate = (Experimental wells - Effector cell spontaneous pores - Target cell spontaneous pores) / (Target cell maximum lysis pores - Target cell spontaneous pores) × 100%

[0111] The in vitro functional verification results of the NbCD5-1C-CAR-T cells prepared in this invention are as follows: Figure 10 As shown, by Figure 10 It can be seen that NbCD5-1C-CAR-T has a good killing effect on target cells, with a killing rate of 75% at an effector-to-target ratio of 10:1. Furthermore, the killing rates at effector-to-target ratios of 10:1, 5:1, 2.5:1, and 1.25:1 are significantly different from those of the control group, and even reach p<0.0001 at 10:1, 5:1, and 2.5:1.

[0112] The in vitro functional validation experiment of the prepared NbCD30-2B-CAR-T was largely the same as above, except that CD8 cells infected with NbCD30-2B-CAR virus were used. + T lymphocytes (NbCD30-2B-CAR-T) were used to kill Karpas-299 cells that highly expressed CD30 at different ratios. The experiment first involved digesting cultured positive target cells, Karpas-299 (CD30-2B-CAR-T), to induce cytotoxicity. + Human T-lymphoma cells), and control negative target cells Raji (CD30) - (human lymphoma cells).

[0113] The in vitro functional verification results of the NbCD30-2B-CAR-T cells prepared in this invention are as follows: Figure 11 As shown, by Figure 11It can be seen that NbCD30-2B-CAR-T has a good killing effect on target cells, with a killing rate of 63% at an effector-to-target ratio of 10:1. Moreover, the killing rate at each gradient effector-to-target ratio is significantly different from that of the control group, and even reaches p<0.0001 at 10:1, 5:1, 2.5:1, 1.25:1, 0.3125:1.

[0114] Example 4: Bispecific CAR-T cell derived from nanobody, CD30 and CD5, and in vitro and in vivo functional validation.

[0115] This invention uses the (GGGGS)4 flexible peptide as a linker sequence to construct a bispecific Nb-CAR structure, namely NbCD30-Linker-NbCD5-CAR, by tandemly linking NbCD30 and NbCD5. Its complete amino acid sequence is shown in SEQ ID NO.21, and the nucleotide sequence encoding this amino acid sequence is shown in SEQ ID NO.22. Using the same method as in Example 3, this invention also constructed a corresponding bispecific CAR-T, named NbCD5-CD30-CAR-T. The function of the prepared bispecific Nb-CAR-T cells was verified through in vitro experiments. The Karpas-299 T-cell lymphoma cell line, which highly expresses CD30 and CD5 after sorting, was selected as positive target cells to verify its ability to kill dual-target cells. Cells expressing only CD30 and very low expression of CD5 target antigen (CD30...) were used... + CD5 - SupT1 was used as an antigen escape model to verify its off-target ability. Raji cells, a lymphoma cell line that does not express CD30 and CD5, were used as negative control target cells in an in vitro killing experiment. Five effector-to-target cell ratio gradients were established: 5:1, 2.5:1, 1.25:1, 0.625:1, and 0.3125:1. The experimental results were analyzed using the lactate dehydrogenase (LDH) method for cytotoxicity. The in vitro functional verification results of NbCD5-1C-CAR-T, NbCD30-2B-CAR-T, and bispecific NbCD5-CD30-CAR-T cells are as follows: Figure 12 As shown, by Figure 12 It is known that Karpas-299 cells, as positive target cells, have significant killing effects, whether they are single-target CD30 / CD5-CAR-T or bispecific CAR-T. In vitro experiments have also shown that for CD30 and CD5 double-positive target cells, bispecific CAR-T can achieve the same killing ability as single-target CD30 / CD5-CAR-T, and has better killing effects at more efficient target ratios of 5:1 and 2.5:1.

[0116] Example 5: Functional Validation of Animal Models

[0117] This invention further validated the function of the constructed NbCD30 / CD5-CAR-T cells in an in vivo mouse tumor-bearing model. Specifically, NCG-immunodeficient mice of similar body size, aged 6-8 weeks, were selected, and each mouse was subcutaneously injected with 6 × 10⁶ NbCD30 / CD5-CAR-T cells in its back. 6 Karpas-299 cells were used, and tumor volume (V = 1 / 2 * major axis * minor axis²) was measured after 7–10 days. When the tumor volume was approximately 100 mm², the tumor volume was considered to be within the range of 100 mm². 3 Mice with homogeneous tumor formation were randomly divided into four groups. T cells were injected into the mice via tail vein infusion. The first group consisted of NC-CAR-T cells infected with an empty CAR vector, the second group consisted of NbCD30-CAR-T cells, the third group consisted of NbCD5-CAR-T cells, and the fourth group consisted of bispecific NbCD30-CD5-CAR-T cells. Each group contained 6 mice, and each mouse received 3 × 10⁻⁶ cells. 6 Simultaneously, three groups of mice were intraperitoneally injected with Huaman IL-2 at a dose of 1-2 μg / mouse, every 2-3 days. The dynamic growth of tumors in each group was monitored longitudinally (tumor volume was measured every 3 days, and mouse survival status was observed). Approximately three weeks after CAR-T cell infusion, mice were euthanized by cervical dislocation to harvest tumors for comparison and subsequent experiments.

[0118] The effects of NbCD5-CAR-T, NbCD30-CAR-T and bispecific NbCD30-CD5-CAR-T cells on in vivo tumors in mouse tumor-bearing models, such as Figure 13 As shown, by Figure 13 It can be seen that, compared with the NC-CAR-T cell control group, NbCD30-CAR-T and NbCD5-CAR-T cells significantly inhibited tumor volume, and the bispecific NbCD30-CD5-CAR-T cells showed significantly stronger inhibitory ability against subcutaneous tumors in mice than single-target cells.

[0119] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A nanobody, characterized in that, The nanobody is an anti-CD5 or anti-CD30 nanobody; the CDR1, CDR2 and CDR3 amino acid sequences of the anti-CD5 nanobody are shown in SEQ ID NO.3, 5 and 7 respectively; the CDR1, CDR2 and CDR3 amino acid sequences of the anti-CD30 nanobody are shown in SEQ ID NO.11, 13 and 15 respectively.

2. The nanobody according to claim 1, characterized in that, The amino acid sequence of the heavy chain variable region of the anti-CD5 nanobody is shown in SEQ ID NO.1; the amino acid sequence of the heavy chain variable region of the anti-CD30 nanobody is shown in SEQ ID NO.

9.

3. A chimeric antigen receptor, characterized in that, It includes a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling domain, and an intracellular signal transduction domain; the antigen-binding domain is the anti-CD5 and / or CD30 nanobody as described in claim 1 or 2.

4. A plasmid, characterized in that, It contains the encoding gene of the nanobody according to claim 1 or 2, or the encoding gene of the chimeric antigen receptor according to claim 3.

5. A recombinant lentivirus, characterized in that, The recombinant lentivirus was prepared from cells transfected with a plasmid containing the encoding gene of the chimeric antigen receptor as described in claim 3.

6. A chimeric antigen receptor immune cell, characterized in that, The cells express the chimeric antigen receptor of claim 3.

7. The method for preparing chimeric antigen receptor immune cells according to claim 6, characterized in that, The gene encoding the chimeric antigen receptor as described in claim 3 is transduced into cells via lentivirus or retrovirus.

8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises the chimeric antigen receptor immune cells as described in claim 6.

9. The use of the chimeric antigen receptor of claim 3, the chimeric antigen receptor immune cell of claim 6, or the pharmaceutical composition of claim 8 in the preparation of a therapeutic agent for T-cell lymphoma.

Citation Information

Patent Citations

  • Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof

    CN105384825A

  • Chimeric antigen receptor targeting CD5 and application thereof

    CN109266667A